Claritev (CTEV) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
9 Nov, 2026Executive summary
Q3 revenue was $268.311M, up 9.1% YoY, and Adjusted EBITDA was $161.972M, up 4.4%; results exceeded expectations.
ACV bookings were ~$27M in Q3 and ~$101M for 9M; more than 50% of YTD bookings came from outside the core payer market.
FY26 guidance was raised, and initial FY27 revenue outlook is at least $1.1B, one year ahead of the prior 2028 target.
Financial highlights
Q3 revenue was $268.311M, up 9.1% YoY; 9M revenue was $770.467M, up 7.2%.
Q3 Adjusted EBITDA was $161.972M, up 4.4% YoY; margin was 60.4% vs. 63.1% a year earlier.
Q3 operating income was $20.627M vs. $10.067M; net loss narrowed to $61.789M from $69.753M, and Adjusted EPS was $1.77.
9M Adjusted EBITDA was $464.685M vs. $451.229M; 9M net loss was $194.575M vs. $203.712M.
Q3 operating cash flow was $18.1M and free cash flow was negative $25.8M; unlevered free cash flow was $104.4M.
Outlook and guidance
FY26 revenue guidance was raised to $1.038B–$1.043B, with midpoint $30.5M above Q2 guidance.
FY26 Adjusted EBITDA guidance was raised to $625M–$630M; free cash flow guidance to $10M–$20M.
FY26 CapEx guidance was narrowed to $165M–$170M; effective tax rate guidance is 24%–28%.
Initial FY27 revenue outlook is at least $1.1B, one year ahead of the prior 2028 target; detailed segment and cash flow guidance is planned with Q4 results.
FY26 ACV bookings are expected at $115M–$125M, up 70%–90% YoY; bookings typically begin converting to revenue in 2–4 quarters.
Latest events from Claritev
- 2027 revenue target advances, with growth diversification and rising free cash flow in focus.CTEV
Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum - AI-driven transformation and new market expansion propel robust growth and operational agility.CTEV
Morgan Stanley 24th Annual Global Healthcare Conference - Transformation drives growth, margin strength, and leadership in healthcare claims innovation.CTEV
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 6.6%, guidance raised, but legal and IT risks remain.CTEV
Q2 2026 - Record bookings, tech investment, and strong client ties drive ambitious 2030 growth targets.CTEV
Bank of America Global Healthcare Conference 2026 - Transformation and innovation drive growth, profitability, and expanded market reach.CTEV
44th Annual J.P. Morgan Healthcare Conference - Six new market segments, tech innovation, and a $200M pipeline drive growth into 2026.CTEV
BofA Securities Leveraged Finance Conference 2025 - Q1 2025 revenue was $231.3M, net loss narrowed, and transformation advanced.CTEV
Q1 2025 - 2024 net loss surged on a $1.49B impairment as transformation and rebranding drive long-term optimism.CTEV
Q4 2024